Mind Medicine Inc (US:MNMD) — Company Overview, News & Financial Data
Mind Medicine is developing psychedelic-inspired treatments for mental health disorders, focusing on innovative therapy methods.
MNMDMind Medicine Inc
Company profile
About Mind Medicine Inc
Mind Medicine (NASDAQ:MNMD) is at the forefront of psychedelic-inspired medicine and therapy development. Traded on the NASDAQ, MNMD is making waves in the life sciences sector with its innovative approach to mental health treatment. The company is focused on developing novel treatments for mental health disorders by leveraging psychedelic substances like LSD, MDMA, and psilocybin. Its project pipeline includes advanced clinical trials aimed at addressing issues such as anxiety, PTSD, and substance use disorders. Mind Medicine's objectives revolve around creating effective, evidence-based treatments while challenging the existing paradigms of mental health care. Their efforts are not just about advancing therapies but also about pioneering a broader acceptance of psychedelics in modern medicine.
Snapshot
Public USOwnership
2019Year founded
74Employees
New York City, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
New York City, US
Products and/or services of Mind Medicine Inc
- Development of psychedelic-assisted therapies seeks to enhance treatments for mental health disorders by using substances like LSD and psilocybin, aiming to effectively address conditions such as anxiety and depression.
- Project Lucy focuses on the therapeutic potential of LSD for treating anxiety disorders, aiming to establish its safety and efficacy through robust clinical trials.
- Exploration of microdosing involves studying the effects of low, sub-hallucinogenic doses of psychedelics on improving cognitive function and mood disorders while maintaining daily functionality.
- Developing digital therapeutics incorporates digital tools to enhance the therapeutic process, supporting patients undergoing treatment with psychedelics through technology-driven applications and monitoring.
- Research collaborations with academic institutions aim at advancing psychedelic science by joining forces in clinical trials, data analysis, and understanding the neurobiological mechanisms of psychedelics.
- Focus on drug development involves synthesizing and testing novel psychedelic compounds to discover new medications and treatment options for a variety of mental health conditions.
Mind Medicine Inc executive team
- Mr. Robert BarrowCEO & Director
- Mr. Mark R. Sullivan J.D.Chief Legal Officer & Corporate Secretary
- Dr. Daniel Rollings Karlin M.A., M.D.Chief Medical Officer
- Dr. Scott M. Freeman M.D.Co-Founder & Clinical Advisor
- Mr. Leonard LatchmanCo-Founder
- Ms. Brandi L. Roberts CPA, M.B.A.Chief Financial Officer
- Mr. Peter MackSenior Vice President of Pharmaceutical Development & Operations
- Ms. Beth CalitriVice President of Corporate Communications
- Ms. Stephanie FaganChief Corporate Affairs Officer
- Dr. Gregg Pratt Ph.D.Chief Regulatory & Quality Assurance Officer